Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Cymbalta

    - PMLiVE

    Lundbeck drops Parkinson’s drug acquired in €905m deal

    Disappointment after drug failed in a mid-stage clinical trial

    - PMLiVE

    Lundbeck gets US approval for migraine drug at heart of Alder takeover

    US regulator clears CGRP inhibitor under Vyepti trade name

    - PMLiVE

    J&J gets EU approval for depression nasal spray Spravato

    Approved with a risk management plan to guard dosing

    - PMLiVE

    Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

    Continues to bulk up its pipeline

    - PMLiVE

    Prescription drug dependence ‘linked to deprivation’, says PHE

    Public Health England publishes review on prescription rates

    - PMLiVE

    Lundbeck’s key products shine in Q2 but problems remain

    Faces increasing patent losses

    - PMLiVE

    Lundbeck snaps up Abide Therapeutics for $400m

    Also acquires its lead drug for Tourette’s syndrome

    - PMLiVE

    Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

    Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’

    - PMLiVE

    Lundbeck and Otsuka start phase III for Rexulti in bipolar

    Drug is also in phase II trial to treat PTSD patients

    - PMLiVE

    Teva poaches Lundbeck’s Schultz as new CEO

    Shares in Lundbeck fall as two senior posts become vacant

    - PMLiVE

    Lundbeck partners with 23andMe on first-of-its-kind study

    Psychiatry collaboration will combine data from genetics, cognitive tests and online surveys

    Lundbeck partners with IBM Watson on drug research

    The deal will also see it set up a new real world evidence platform

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links